Cerebrolysin: the Austrian neuropeptide with forty years of stroke data.

Cerebrolysin is the kind of compound American pharmacology textbooks tend to omit. It has been on the European market for four decades, sits in the formularies of more than fifty national health systems, has been the subject of more than a hundred randomized trials and meta-analyses, and remains unavailable in the United States — neither approved nor banned, simply foreign. The reason for the omission is partly mechanism (it is a mixture, not a single molecule, which the FDA's modern approval pathway does not love) and partly geography (most of the trials are run in Eastern Europe, Russia, China, India, Pakistan, and Egypt, and indexed in journals American clinicians do not regularly read). The literature is, nevertheless, substantial and worth understanding on its own terms.

What it is and how it is made

Cerebrolysin is produced at EVER Neuro Pharma's facility in Unterach am Attersee, Austria. The starting material is porcine brain tissue. The manufacturing process is enzymatic hydrolysis under standardized conditions: a controlled proteolytic digest yields a low-molecular-weight peptide fraction (under 10 kDa) plus free amino acids. EVER Pharma describes the active fraction as containing peptides with sequence homology to brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), nerve growth factor (NGF), and ciliary neurotrophic factor (CNTF) — endogenous proteins that maintain neurons, support synapse formation, and drive recovery after injury.

Mechanistically, the consensus across forty years of experimental work is that Cerebrolysin acts as a multimodal neurotrophic mimetic. It crosses the blood-brain barrier. It reduces glutamate excitotoxicity in vitro. It quiets microglial activation. It dampens caspase-3-mediated apoptosis. It supports neurogenesis in the dentate gyrus and subventricular zone in animal models. No single mechanism dominates the data.

What the 2025–2026 stroke data look like

The most carefully designed recent work comes from Jacek Staszewski's group at the Military Institute of Medicine in Warsaw. Their 2025 paper in Translational Stroke Research, on a propensity-matched cohort of patients undergoing endovascular thrombectomy for acute ischemic stroke, reported that adjunctive Cerebrolysin (30 mL/day for 21 days post-thrombectomy) was associated with markedly higher rates of modified Rankin Scale 0–2 at 90 days (68 percent versus 44 percent in matched controls), a lower rate of secondary intracerebral hemorrhage (14 percent versus 40 percent), and lower NIHSS scores at day 7. The 12-month extension, published in February 2026, reported sustained benefit: adjusted odds ratio 6.10 for 12-month functional independence.

From Pakistan, an October 2025 systematic review and meta-analysis pulled fourteen randomized controlled trials together — 2,884 patients — and reported a statistically significant improvement in early NIHSS recovery with adjunctive Cerebrolysin and no increased rate of serious adverse events.

Beyond stroke: a 2025 Russian imaging study that explains why

The CEREHETIS trial, run by M. N. Kalinin and D. R. Khasanova at Kazan State Medical University, used multimodal MRI to look. Their 2025 paper in Zh Nevrol Psikhiatr reported that at day 14 post-stroke, Cerebrolysin-treated patients showed preserved diffusion tensor imaging metrics in the infarct zone, lower blood-brain barrier permeability, and smaller final infarct volume than thrombolysis-only controls.

What the imaging shows is not a dramatic intervention. It is a quieter brain. Less edema. Less barrier leak. Less microstructural damage at the infarct edge.

The Alzheimer's data: smaller, but unusually direct

A 2022 randomized controlled trial published in the Journal of Alzheimer's Disease, led by X. Antón Alvarez at the Medinova Institute of Neurosciences in A Coruña, Spain, in collaboration with EVER Pharma and UC San Diego, did something most cognition trials do not: it measured pathology directly. Plasma neuronal-derived extracellular vesicles were collected from 110 AD patients before and after treatment with Cerebrolysin alone, donepezil alone, or both. The combination significantly reduced vesicle Aβ42 levels relative to monotherapy, and Cerebrolysin specifically reduced total tau, P-T181-tau, and P-S396-tau more than donepezil monotherapy did.

Beyond the obvious

The CLINCH trial — investigator-led, multicenter, randomized, open-label, blinded endpoint — is currently enrolling 88 patients with primary lobar intracerebral hemorrhage in Poland to test whether Cerebrolysin given within 6 hours of onset improves 90-day functional outcomes. Hemorrhagic stroke has had essentially zero therapeutic progress since the 1990s. If CLINCH or its successor trials read positive, the implication is large.

Often studied alongside

In Russian neuroprotection research, Cerebrolysin appears alongside Semax — the seven-amino-acid ACTH(4-10) analog developed at the Russian Academy of Sciences. The two compounds are mechanistically distinct (Semax acts on melanocortin receptor pathways and modulates BDNF expression; Cerebrolysin's neurotrophic peptide fraction acts more diffusely) but the clinical use cases overlap. Selank, Semax's anxiolytic counterpart, occasionally appears in the same protocols.

Practical considerations

Cerebrolysin is an aqueous solution, supplied in clear ampoules. Storage is at controlled room temperature, protected from light. Standard clinical doses in the European literature are 10–50 mL/day given as a slow IV infusion or IV push, typically for 10–21 day courses. The product is not approved by the US FDA; it remains a research compound under US law.